Mad Hedge Biotech and Healthcare Letter
November 10, 2022
Fiat Lux
Featured Trade:
(A RARITY IN A CHAOTIC MARKET)
(PGNY)
Mad Hedge Biotech and Healthcare Letter
November 10, 2022
Fiat Lux
Featured Trade:
(A RARITY IN A CHAOTIC MARKET)
(PGNY)
Infertility is one of the most common health concerns in the United States.
According to the Centers for Disease Control and Prevention, among heterosexual women between 15 and 49 years old without prior births, about 1 in every 5—or 19%—could not get pregnant after 1 year of trying.
Meanwhile, about 1 in 4, or 26%, of women in this category experience difficulty conceiving or carrying a pregnancy to full term.
The US Census Bureau also disclosed that the average age of women planning to get pregnant has climbed from 27 to 30—the highest ever recorded. Consequently, when some women start trying to have a baby at a later age, they encounter more challenges because of a decline in fertility.
Based on recent CDC data, 12.2% of couples struggle with infertility. Male infertility accounts for 1/3, females for 1/3, and the rest is a combination.
Treatment, although available, is typically costly. Known therapies include surgery, assisted reproductive technology like IVF, and drugs.
Due to the problems linked to affordability, employers have been attempting to cover fertility treatments in their employee health plans. This practice has become more common in recent years as companies strive to focus more on equity and diversity.
Based on a survey by Mercer, 42% of major companies with 20,000 or more workers included IVF treatments and 19% covered egg freezing in their health plans in 2020. This is a notable leap from the 36% and 6% recorded in 2015, respectively.
Needless to say, adding fertility benefits as part of the coverage serves as a tool that enables employers to stand out in a highly competitive labor market.
This is where Progyny (PGNY) comes in.
Progyny is a rarity amid the chaotic market of 2022. That is, it is a growth company that managed to outperform the overall market.
Progyny is a specialized company that offers fertility benefits management services. It is supported by a vast network of fertility experts, with 900 specialists spread across 650 clinics throughout the US.
The company leverages its network of experts and combines their knowledge with a data-driven model to provide a service to employers with employees trying to get pregnant.
Progyny basically gathers the resources available to the clients and providers and makes these materials not only more easily accessible but also more effective.
It has a Smart Cycle program, which enables subscribers or members to customize or modify their treatment plans.
The companies can control the costs given the comprehensive information and availability of experts to consult. In turn, this can offer more attempts to get pregnant without the fear of health plan coverage running out in the middle of treatment.
What is the potential of this business?
Progyny has steadily expanded since its creation in 2016. Its revenue has more than doubled since then, rising from $229.7 million in 2019 to $500.6 million in 2021.
Given its trajectory, the company’s revenue is expected to increase by 47% to 55% by 2022.
Progyny recorded strong growth in the third quarter of 2022. Its sales jumped by 68% to reach $205.4 million, beating analysts’ projections of $194.5 million.
The company also boosted its full-year guidance for 2022 from $755 million to $780 million and continues to add new clients while impressively retaining almost 100% of its existing customers.
The long-term outlook for Progyny is promising as the market value for fertility platforms and services is estimated to grow at a 4.7% compound annual rate until 2030. By then, the market would be worth roughly $48 billion.
After all, more and more individuals are looking into fertility services, which means employers will keep viewing this benefit as a requirement. That means there wouldn’t be any concerns regarding any short-term drop-off in the demand for Progyny’s services.
This should indicate consistent, if not continuously growing, revenue.
With a market capitalization of a little above $4 billion, Progyny is a promising long-term investment as it is a pioneer in a lucrative market that’s just begging to be disrupted.
Legal Disclaimer
There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visist to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Vimeo and Youtube video embeds: